Concurrent whole brain radiotherapy and bortezomib for brain metastasis by Lao, CD et al.
Lao et al. Radiation Oncology 2013, 8:204
http://www.ro-journal.com/content/8/1/204RESEARCH Open AccessConcurrent whole brain radiotherapy and
bortezomib for brain metastasis
Christopher D Lao1*, Judah Friedman2, Christina I Tsien3, Daniel P Normolle4, Christopher Chapman3, Yue Cao3,5,
Oliver Lee3, Matt Schipper3, Catherine Van Poznak1, Daniel Hamstra3, Theodore Lawrence3, James Hayman3
and Bruce G Redman1Abstract
Background: Survival of patients with brain metastasis particularly from historically more radio-resistant
malignancies remains dismal. A phase I study of concurrent bortezomib and whole brain radiotherapy was
conducted to determine the tolerance and safety of this approach in patients with previously untreated brain
metastasis.
Methods: A phase I dose escalation study evaluated the safety of bortezomib (0.9, 1.1, 1.3, 1.5, and 1.7 mg/m2)
given on days 1, 4, 8 and 11 of whole brain radiotherapy. Patients with confirmed brain metastasis were recruited
for participation. The primary endpoint was the dose-limiting toxicity, defined as any ≥ grade 3 non-hematologic
toxicity or grade ≥ 4 hematologic toxicity from the start of treatment to one month post irradiation. Time-to-Event
Continual Reassessment Method (TITE-CRM) was used to determine dose escalation. A companion study of brain
diffusion tensor imaging MRI was conducted on a subset of patients to assess changes in the brain that might
predict delayed cognitive effects.
Results: Twenty-four patients were recruited and completed the planned therapy. Patients with melanoma accounted
for 83% of all participants. The bortezomib dose was escalated as planned to the highest dose of 1.7 mg/m2/dose. No
grade 4/5 toxicities related to treatment were observed. Two patients had grade 3 dose-limiting toxicities
(hyponatremia and encephalopathy). A partial or minor response was observed in 38% of patients. Bortezomib showed
greater demyelination in hippocampus-associated white matter structures on MRI one month after radiotherapy
compared to patients not treated with bortezomib (increase in radial diffusivity +16.8% versus 4.8%; p = 0.0023).
Conclusions: Concurrent bortezomib and whole brain irradiation for brain metastasis is well tolerated at one month
follow-up, but MRI changes that have been shown to predict delayed cognitive function can be detected within one
month of treatment.
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The development of metastatic disease to the brain
often reflects a poor prognosis, with a median survival
measured in months. Survival of patients with brain
metastasis from historically more radio-resistant malig-
nancies (i.e., melanoma and renal cell carcinoma) is par-
ticularly dismal. Of patients who develop symptomatic
melanoma brain metastases, the metastases are fatal in* Correspondence: clao@umich.edu
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reproduction in any medium, provided the orup to 95% of cases [1]. Despite the recent improvements
in treatment for metastatic melanoma death from mela-
noma brain metastasis continues to be a critical barrier
to improved survival [2-4].
Whole brain radiotherapy (WBRT) can have an im-
pact on CNS progression, neurologic decline, and the
likelihood of death from cerebral metastases, but such
treatment has not demonstrated an overall survival
benefit as primary therapy [5]. Radio-sensitization has
been attempted in melanoma but the results have been
underwhelming [6]. The promise of such an approach,
however, is still important to explore. Bortezomib. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteasome inhibitor with preclinical and clinical data
supporting activity against a variety of neoplasms. For
melanoma, there does not appear to be much activity as
a single agent but its potential role as a radiosensitizer is
promising [7-9]. Concurrent use of bortezomib and
radiation to treat metastatic disease to the brain has not
been assessed previously, thus, a phase I study of
concurrent bortezomib and whole brain radiotherapy in
untreated patients predominantly with melanoma was
conducted.
Methods
Eligibility
Men and women aged 18 years of age or older with a
histopathologically confirmed solid tumor malignancy
and clinical evidence of metastatic disease to the brain
were considered for enrollment. The study was initially
designed only for patients with melanoma and renal cell
carcinoma, but was later expanded to other solid
tumors with documented brain metastases. The study
was approved by the University of Michigan Institu-
tional Review Board (IRB) and signed informed consent
was obtained for study enrollment. Study participation
required one or more brain metastases on contrast-
enhanced brain MRI for which WBRT was a treatment
option, and in the judgment of the treating physician
beginning additional systemic therapy (e.g., chemo-
therapy) could wait at least 30 days from completion of
WBRT. Patients who had brain metastases managed
with radiosurgery or surgery in the past were eligible as
long as they had not received WBRT. Other enrollment
criteria included: an estimated survival of at least
8 weeks, Karnofsky performance score (KPS) of at least
70%, adequate hematologic, hepatic, cardiovascular and
renal function, and completion of previous chemo-
therapy at least 2 weeks before starting WBRT. Females
of child bearing potential must have had confirmation
they were not pregnant and acceptable contraception
was required for the duration of the study.
Patients were considered ineligible if they had received
previous radiotherapy to the head or neck, WBRT, or
prior bortezomib therapy. Female patients who were preg-
nant or breast-feeding or patients with ≥Grade 2 peri-
pheral neuropathy within 14 days before enrollment, class
III or IV congestive heart failure or serious concurrent
cardiac disease, hypersensitivity to boron or mannitol, or
serious medical or psychiatric illness likely to interfere
with participation were ineligible.
Study procedures
Within seven days of registration, a complete history
and general physical exam, including neurological exa-
mination was performed, as well as determination ofKPS immediately prior to the beginning of protocol
treatment. Documentation of steroid and anticonvulsant
doses, complete blood count with differential and plate-
let count (CBCDP), and comprehensive chemistry pro-
file were obtained. An MRI with gadolinium contrast
was performed within 3 weeks prior to the start of the-
rapy. During the treatment period, all participants were
evaluated weekly by physical exam, including neuro-
logical examination and examination of the skin within
the radiation treatment portal. Documentation of toxi-
cities, KPS, and both steroid and anticonvulsant use
were performed at each evaluation. A complete blood
count with differential was performed prior to each dose
of bortezomib. At the completion of WBRT, patients
were evaluated once every two weeks for an additional
month which completed study participation. Brain
imagingwas obtained one month after completion of
radiotherapy and then as clinically indicated approxi-
mately every 2 to 3 months. Following the first month
post-irradiation, patients were seen and treated as clini-
cally indicated.
Radiation treatment
Adequate immobilization and reproducibility of position
was ensured using thermoplastic masks. The target vol-
ume included the whole brain and meninges to the for-
amen magnum. Doses were specified at central axis at
mid-plane. Radiation was delivered with a daily fraction
size of 2.5-3.0 Gy per fraction given 5 days a week, for a
total dose of 30–37.5 Gy. The Radiation Oncology
treating physicians were allowed to determine the most
appropriate treatment fractionation scheme (30 Gy in
3 Gy fractions or 37.5 Gy in 2.5 Gy fractions) for pa-
tients independent of bortezomib. Treatment was deliv-
ered using photon beam energies of 6 megavolts (MV).
Bortezomib
Bortezomib for this study was provided by Millennium
Pharmaceuticals, Inc. (Cambridge, Massachusetts). It is a
small molecule proteasome inhibitor currently approved
by the United States Food and Drug Administration and
registered in Europe for the treatment of multiple mye-
loma. Bortezomib was given by rapid IV injection begin-
ning on day 1 of radiation, at least one hour prior to
radiation treatment. During the radiation therapy period,
bortezomib was given twice per week (at least 72 hours
apart) for a total of 4 doses (given on days 1, 4, 8, and 11).
Dose assignment
The bortezomib dose was assigned using TITE-CRM
method [10]. The primary objective of the study was to
determine the dose of bortezomib associated with a 20%
probability of DLT. A DLT was defined as the develop-
ment of any ≥ grade 3 non-hematologic toxicity or ≥
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tute Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0 that was possibly, probably or
definitely attributed to bortezomib and/or WBRT identi-
fied up to thirty days following treatment. Before each
drug dose, the patient was evaluated for possible toxic-
ities that may have occurred after the previous dose(s).
The trial planned to accrue 30 patients evaluable for
toxicity.
As in all CRM and TITE-CRM trials, before the
enrollment of the first patient, the expected probability
of DLT at each dose was elicited from the clinical inves-
tigators by the statistician, who used this information to
construct the prior estimate of the dose-toxicity func-
tion, a one-parameter logistic function. As each patient
completed the trial, the dose-toxicity function was re-
estimated, and the re-estimated function was used as
patients presented for enrollment to calculate the esti-
mated probability of DLT at each dose. Each newly
enrolled patient was thereby assigned to the bortezomib
dose with estimated probability of toxicity closest to but
not exceeding the target rate, 0.20.
Data analysis
The primary objective was to estimate the dose-toxicity
function of bortezomib by means of a Bayesian logistic
regression model, logit(π) = a + b × d, where π is the
probability of toxicity, a and b are logistic regression pa-
rameters estimated from the dose and toxicity data, and
d is dose of bortezomib. The secondary objective was to
assess the response to the combination of bortezomib
and WBRT by MRI or contrasted CT. Response criteria
followed guidelines proposed by MacDonald et al. [11].
Brain imaging
A companion University of Michigan IRB approved
imaging study was conducted to assess MRI findings
that might reflect changes in blood brain/tumor per-
meability in patients with brain metastases during and
after radiotherapy. Patients enrolled in the Phase I
bortezomib study were eligible to participate in the con-
current imaging study. Diffusion tensor imaging (DTI),
which measures water diffusivity around axons and
reflects the degree of demyelination, was used to evaluate
a subset of patients enrolled to the concurrent WBRT-
bortezomib study. All participating patients provided
separate written informed consent for this study. Patients
underwent brain MRI scans at three time points:
1–2 weeks pre-RT, within one week of finishing RT
(end-RT), and one month after finishing RT (post-RT). All
MRI scans were done on a single 3 T Phillips Achieva
scanner. Functional Imaging Analysis Tool (FIAT), an
imaging software package developed at the University of
Michigan, was employed prior to Tract Based SpatialStatistics (TBSS). Details of these techniques and analysis
were presented or published previously [12-15].
Results
Patient and treatment characteristics
Twenty-seven patients were screened for enrollment
from January 29, 2007 to June 9, 2009. Twenty-four
patients initiated and completed therapy on protocol,
and represent the evaluable per-protocol sample. Enroll-
ment was stopped at twenty-four despite the planned
thirty as an adequate number of subjects had been
accrued to the highest dose level. Three patients were
considered ineligible due to either prior head and neck
irradiation, rapid progression of disease or concomitant
therapy that was not allowed. Twenty-three of the
twenty-four patients (96%) received the planned four
doses of bortezomib. Fifty-eight percent of patients were
female and the median age was 58 years. The majority of
patients had not received prior systemic therapy (67%).
Patients with melanoma accounted for 83% of all partici-
pants. The median number of brain metastases was five
and 50% of patients had neurologic symptoms related to
disease at baseline (Table 1).
The bortezomib dose was escalated per-protocol via
TITE-CRM from 0.9 mg/m2 to 1.7 mg/m2, with the lar-
gest cohort of patients (n = 9) receiving the highest dose
level. A total radiation dose of 30 Gy was administered
to 79% of patients and 37.5 Gy was administered to 21%
of patients. All patients treated with 37.5 Gy (n = 5) were
in the highest dose cohort (Table 1).
Toxicities
The relationship between bortezomib dose and DLT is
depicted in Figure 1. The estimated P(DLT) at 1.7 mg/m2
is 0.15, with a one-sided 90% credible interval extending
to 0.24. No grade 4/5 toxicities were observed that were
related to treatment. The most frequent toxicity noted
was fatigue (54% of patients) (Table 2). Two grade 3 DLTs
were observed (hyponatremia and encephalopathy). Hypo-
natremia occurred in a patient treated at 0.9 mg/m2 and
resolved after completion of protocol treatment. Encepha-
lopathy developed in a patient treated at 1.7 mg/m2. This
patient was admitted to the hospital for management prior
to receiving all planned bortezomib doses. Symptoms
were initially considered secondary to tapering of dexa-
methasone with improved symptoms following escalation
of the steroid dose. Seizure activity could not be ruled out,
but no antiepileptic medications were started. Imme-
diately prior to the fourth bortezomib dose the patient
developed expressive aphasia that prompted a second
admission and precluded administration of additional
bortezomib. Radiotherapy was completed as planned.
Within four weeks of completion of protocol therapy the
patient’s course was complicated by gastric perforation
Table 1 Patient and treatment characteristics at baseline
No. of patients
Screened 27
On-study 24
Gender, n (%)
Female 14 (58)
Male 10 (42)
Median age, years (range) 58 (41–76)
Underlying malignancy, n (%)
Melanoma 20 (83)
Non-small cell lung cancer 2 (8)
Renal cell carcinoma 1 (4)
Breast 1 (4)
No. previous systemic therapies
Median (range) 0 (0–9)
No. of brain metastases
Median (range) 5 (1-≥ 10)
Neurologic symptoms at baseline, n (%)
Yes 12 (50)
No 12 (50)
Dexamethasone use, n (%)
Yes 17 (71)
No 7 (29)
Craniotomy*, n (%)
Yes 2 (8)
No 22 (92)
Anti-epileptic medication use, n (%)
Yes 2 (8)
No 22 (92)
Bortezomib dose (mg/m2/dose), n (%)
0.9 5 (21)
1.1 4 (17)
1.3 4 (17)
1.5 2 (8)
1.7 9 (37)
Radiation dose, n (%)
30 Gy (3 Gy fractions) 19 (79)
37.5 Gy (2.5 Gy fractions) 5 (21)
*One patient underwent craniotomy and was rendered disease-free in the
brain after progressing on protocol therapy.
Figure 1 Results of Markov Chain Monte Carlo estimation of
dose-toxicity function. Posterior estimate of dose-toxicity function
(black curve) with one-sided, 90% credible region (gray area). Vertical
lines are 90% one-sided exact confidence intervals for per-dose
probability of toxicity (tick marks). Numbers at the top are #DLTs/#
evaluable patients.
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prolonged steroid exposure and stress ulcers. During that
admission an electroencephalogram was performed and
revealed diffuse slowing consistent with encephalopathy.
Her symptoms did not significantly improve and she
ultimately died from disease progression. This patient was
not included in the companion brain imaging study.Response and survival
Twenty-one of twenty-four patients were evaluable for
radiologic response in the brain. The three patients
without adequate surveillance brain imaging had clinical
evidence of progressive disease and continued on with
supportive care alone that precluded repeat imaging. No
complete responses were observed. A partial response
(PR) in the brain was observed in 17% of patients, a
minor response (mPR) in 21% of patients, and stable
disease (SD) in 33% of patients. Partial responses and
SD were observed across all cohorts. Survival data was
available on all 24 patients. Median survival for the
study population was 5 months (range 1.5 to 17 months)
(Table 3). The relationships between dose and response
and survival were not statistically significant, but the
study was not formally powered for these endpoints.
Brain imaging
In the companion diffusion tensor MRI study to assess
normal white matter radiation response, 23 patients with
brain metastasis from any cancer treated with WBRT
were enrolled. Twelve of those patients had completed
at all three study MRIs (pre-RT, end-RT, post-RT) and
met predetermined criteria for image quality, including
no edema, mass effect, or metastases >5 mm diameter in
the examined white matter tracts [13]. Of the 12 patients
that completed imaging at one month post-RT, 8 (all
with melanoma) received bortezomib on the phase I
WBRT-bortezomib study and were compared to the
Table 2 Adverse events possibly to definitely related to treatment
Toxicity Bortezomib dose level*
0.9 (n = 5) 1.1 (n = 4) 1.3 (n = 4) 1.5 (n = 2) 1.7 (n = 9)
Gr.1-2 Gr.3-4 Gr.1-2 Gr.3-4 Gr.1-2 Gr.3-4 Gr.1-2 Gr.3-4 Gr.1-2 Gr.3-4
Neurologic
Headache 2 4
Neuropathy 1
Confusion 1
Memory impairment 1 1
Tinnitus 1 1
Speech impairment 1
Muscle weakness 1
Hearing impairment 2
Seizure 1
Encephalopathy 1#
Gastrointestinal
Nausea/vomiting 1 5
Diarrhea 1
Laboratory
Hyponatremia 1#
Other
Fatigue 3 2 3 1 4
Alopecia 3 1 1
Sweating 1
Edema 1
Mucositis 1 1
Pain (scalp) 1 1
Pain (extremity) 1
Chills/rigors 1
Skin
Radiation dermatitis 1 3 4 1
Dry skin 1
Rash 1
Pruritus 1
*mg/m2/dose.
#Dose limiting toxicity.
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four patients that did not receive bortezomib had cancer
types other than melanoma. Of the 8 bortzemib patients,
2 received 37.5 Gy and 6 received 30 Gy. Of the 4
patients who did not receive bortezomib, 2 received
37.5 Gy and 2 received 30 Gy. In the 8 patients who
received bortezomib, there was a significantly greater
increase of radial diffusivity in hippocampus-associated
white matter as compared to other white matter areas
(Table 4). In the remaining 4 patients that did not
receive bortezomib, there was no significant difference
in the change of radial diffusivity between hippocampus-associated and other white matter structures. At the one
month post-RT follow-up, there was a persistent greater
increase in radial diffusivity in hippocampus-associated
white matter in patients that received bortezomib than
in patients that did not receive bortezomib (p = 0.0023;
Figure 2).
Discussion
Bortezomib is a proteasome inhibitor with independent
activity against various cancers and has demonstrated
activity as a radiosensitizer in preclinical models [8].
Much of the preclinical work on proteasome inhibition
Table 3 Response and survival
Best response in brain# Median survival
CR PR mPR SD PD months (range)
Study population (n = 24)* 0 4 (17%) 5 (21%) 5 (21%) 8 (33%) 5 (1.5–17)
Bortezomib dose group
(mg/m2/dose)
0.9 (n = 5) 0 1 (20%) 0 1 (20%) 3 (60%) 7 (5–11)
1.1 (n = 4) 0 2 (50%) 1 (25%) 1 (25%) 0 5.8 (2.5–7)
1.3 (n = 4) 0 0 3 (75%) 0 1 (25%) 9.5 (5–12.5)
1.5 (n = 2) 0 0 0 0 2 (100%) 11 (5–17)
1.7 (n = 9)¶ 0 1 (11%) 1 (11%) 3 (33%) 2 (22%) 4 (1–8)
Radiation dose
30 Gy (3 Gy fractions) 0 4 (100%) 4 (100%) 2 (25%) 7 (87.5%) 7 (1.5–17)
37.5 Gy (2.5 Gy fractions)† 0 0 (0%) 0 3 (75%) 1 (12.5%) 4 (1.5–8)
* Pre- and post- treatment brain MRI or CT with contrast available on 22 patients.
# CR: complete response; PR: partial response; mPR: minor response; SD: stable disease; PD: progressive disease.
¶ Pre- and post-treatment brain MRI or CT with contrast available on 7 of 9 patients. Survival data available on all patients.
† Pre- and post-treatment brain MRI or CT with contrast available on 4 of 5 patients treated with 37.5 Gy.
Lao et al. Radiation Oncology 2013, 8:204 Page 6 of 8
http://www.ro-journal.com/content/8/1/204and radiation sensitization has focused on the role of
nuclear factor kappa B (NF- κB) [9]. In many cancer cell
models, radiation treatment results in the activation of
NF- κB which might act to inhibit apoptosis. In mela-
noma, however, as well as other cancer cell types, NF- κB
is constitutively activated which could further mediate
resistance to radiation therapy. Proteasome inhibition can
result in the prevention of NF- κB activation, which may
result in improved responses and outcomes. Other effects
on DNA repair and survival pathways may also contribute,
including suppression of homologous recombination,
down-regulation of Bcl2, Bxl1, survivin, XIAP and in-
creases in Fas/Fas ligand [16,17].
Data on concurrent bortezomib and radiotherapy is
limited. Pugh et al. [18] performed a phase I study of
bortezomib and radiotherapy for patients who were can-
didates for palliative radiation to sites other than central
nervous system and bone. Doses up to 1.6 mg/m2 IV for
4 doses starting on day 1 of radiotherapy were given. No
DLTs were observed. O’Neil et al. [19] performed a
phase I study of 5-fluorouracil and bortezomib concur-
rent with RT for rectal cancer. Diarrhea was the doseTable 4 Diffusion tensor imaging bortezomib interaction effe
group and white matter structures
Group Structures Pre-
Change in RD
No bortezomib Other white matter + 10.4%
Hippocampus-associated + 13.2%
With bortezomib Other white matter + 7.7%
Hippocampus-associated + 17.2%
*Pre-RT to End-RT: total n = 14, n = 9 with bortezomib.
#Pre-RT to 1 month post-RT: total n = 12, n = 8 with bortezomib.
¶Comparison of changes in hippocampus-associated structures to other white mattlimiting toxicity at the 1 mg/m2/dose level but NF- κB
activation did not appear to be suppressed at that dose.
Kubicek et al. [20] performed a phase I of concurrent
bortezomib (up to 1.3 mg/m2/dose) and temozolomide
with WBRT for primary central nervous system malig-
nancies (85% had glioblastoma). Forty-four percent had
previously received RT. Grade 3 headache, syncope,
neuropathy, hyponatremia, dyspnea, stupor were ob-
served but none were considered DLTs.
In our study of concurrent bortezomib and whole brain
irradiation, we administered one cycle of bortezomib and
observed only two DLTs up to 1.7 mg/m2/dose up to one
month post treatment in previously untreated patients
with metastatic cancer. The patient who developed grade
3 encephalopathy was symptomatic at baseline from mul-
tiple brain metastases, was the oldest patient enrolled
(76 years old), and was heavily pretreated for her disease
(breast cancer, estrogen receptor/progesterone receptor
positive, HER2/neu negative). These factors may have
contributed to the severity of this adverse event and it is
unclear how much the bortezomib added to radiation
contributed to the observed encephalopathy.ct. Changes in radial diffusivity (RD) values by treatment
RT to End-RT* Pre-RT to 1 month post-RT#
95% CI Change in RD 95% CI
6.3 – 14.5% + 5.8% 1.1 – 10.5%
7.5 – 18.8% + 4.8% −1.4 – 11.1%
4.6 – 10.8% + 8.1% 4.8 – 11.5%
13.0 – 21.5% + 16.8%¶ 12.4 – 21.2%
er structures p-value = 0.0023.
Figure 2 Radial diffusivity changes with and without bortezomib in hippocampus-associated white matter. Y-axis: Percent difference in
radial diffusivity changes between hippocampus-associated and other white matter. *p < 0.05, **p = 0.0007 (for difference from 0%).
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metastatic disease can be challenging and alternative
strategies to adequately monitor patients are critical
[21]. In this study, a Time-to-Event Continual Reassess-
ment Method (TITE-CRM) design was used to optimize
accrual with dose assignment determined by acute
effects. Late radiation effects from brain irradiation,
however, are exceptionally difficult to use as a dose li-
miting toxicity (DLT) in a phase I study. In the current
study, the late radiation effects from irradiation were
not formally assessed given the technical and practical
difficulties in following a patient for months to deter-
mine toxicities prior to enrolling another patient. How-
ever, late effects are a critical part of assessing toxicities
from brain irradiation as it is already recognized as a
major issue in the pediatric survivorship population
[22]. A number of investigators have attempted to assess
delayed toxicities from radiation using surrogate ima-
ging markers [23]. The understanding of the biologic
causes of late cognitive decline are limited but evidence
supports white matter loss resulting from demyelination
and axonal degradation as key components which can
be exploited as predictors of late cognitive impairment.
Diffusion tensor imaging which assesses the diffusion of
water around axons as a measure demyelination may be
one of the best methods to determine this [24]. In the
current study, the number of patients participating in
the companion study with adequate follow-up was li-
mited but the findings are strongly suggestive of white
matter damage that did not recover four weeks after
completion of RT for those who received bortezomib.
No formal assessment of cognition was included in this
study, but late cognitive impairment could be expected
if patients survived longer [25]. With the expected im-
provement in therapeutic approaches for melanoma in
particular, this issue will be critical [4].Although bortezomib concurrent with WBRT did ap-
pear to have activity (59% had a PR, mPR or SD), which
is historically better than what would be expected with
WBRT alone for these typically radio-resistant malignan-
cies, the median overall survival (5 months) was similar
to what might be expected in this population at the time
this study was conducted [6]. It is not possible from this
study to quantify the contribution of bortezomib to
WBRT.
Conclusions
Bortezomib appears to be well tolerated up to 30 days
after completion of administration of up to 1.7 mg/m2
when given concurrently with WBRT; however, changes
in the normal brain were already evident at the end of
RT and disease control appeared limited. Future studies
testing concurrent brain irradiation with more promising
therapeutic agents should employ techniques to monitor
for changes in the normal brain that could predict
delayed cognitive impairment.
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